title: [Clinical characteristic and outcomes of lung cancer patients with venous thromboembolism].
abstract: OBJECTIVE
  To explore the clinical characteristics and outcomes of lung cancer patients with venous thromboembolism (VTE).
  
  
  METHODS
  The clinical data of 80 lung cancer patients with VTE hospitalized from January 2003 to April 2013 at our hospital were reviewed. The clinical factors of age, gender, clinical manifestations, pathological type, clinical stage, performance status and therapeutic regimen were recorded and analyzed. And the pulmonary thromboembolism (PTE) patients with deep venous thrombosis (DVT) were enrolled into PTE group. The occurrences, clinical manifestations and prognosis of VTE were evaluated.
  
  
  RESULTS
  A total of 80 patients were enrolled. There were 40 males and 40 females with a mean age of (65.8 ± 11.3) years. Adenocarcimoma was identified in 58 (72.5%) patients and advanced lung cancer in 71 (88.8%) patients. Among 37 (46.3%) patients with histodifferentiation results, 89.2% (33/37) of them were moderately and/or poorly differentiated. In 32 (40.0%) patients on chemotherapy, 71.9% (23/32) of them received a platinum-based regimen. There were 35 (43.8%) pulmonary thromboembolism embolism (PTE) and 45 (56.2%) DVT patients. Among PTE patents, 14 (40.0%) were identified incidentally. Dyspnea and swollen of limb were the most common symptoms. Only 20.0% (16/80) patients received VTE prophylaxis. After a definite diagnosis of cancer, 73.8%, 77.5%, 82.5% and 85.0% of patients experienced an event within 3, 6, 9 and 12 months respectively. Up to April 2014, among 53 deceased patients, 77.4% (41/53) died from lung cancer, 9.3% (5/53) PTE while 13.2% (7/53) due to other causes. The cumulative mortality rates within 3, 6, 9 and 12 months after VTE event were 49.1%, 67.9%, 77.4% and 79.2% respectively.
  
  
  CONCLUSIONS
  Adenocarcimoma, advanced lung cancer, poor histodifferentiation and platinum-based chemotherapy regimen are the risk factors of VTE in lung cancer patients. Most events of VTE occur within 3-6 months after a diagnosis of lung cancer while most mortality cases within 1 year after VTE events.
authors.affiliation: National Clinical Research Center for Respiratory Diseases, Department of Respiratory and Critical Care Medicine, Beijing Hospital, Beijing 100730, China.
authors.forename: Xiaomao
authors.initials: X
authors.lastname: Xu
authors.affiliation: National Clinical Research Center for Respiratory Diseases, Department of Respiratory and Critical Care Medicine, Beijing Hospital, Beijing 100730, China.
authors.forename: He
authors.initials: H
authors.lastname: Yang
authors.affiliation: National Clinical Research Center for Respiratory Diseases, Department of Respiratory and Critical Care Medicine, Beijing Hospital, Beijing 100730, China.
authors.forename: Lisong
authors.initials: L
authors.lastname: Qiao
authors.affiliation: National Clinical Research Center for Respiratory Diseases, Department of Respiratory and Critical Care Medicine, Beijing Hospital, Beijing 100730, China.
authors.forename: Zheng
authors.initials: Z
authors.lastname: Tan
authors.affiliation: National Clinical Research Center for Respiratory Diseases, Department of Respiratory and Critical Care Medicine, Beijing Hospital, Beijing 100730, China.
authors.forename: Jin
authors.initials: J
authors.lastname: Jin
authors.affiliation: National Clinical Research Center for Respiratory Diseases, Department of Respiratory and Critical Care Medicine, Beijing Hospital, Beijing 100730, China.
authors.forename: Yiming
authors.initials: Y
authors.lastname: Jin
authors.affiliation: National Clinical Research Center for Respiratory Diseases, Department of Respiratory and Critical Care Medicine, Beijing Hospital, Beijing 100730, China.
authors.forename: Baomin
authors.initials: B
authors.lastname: Fang
authors.affiliation: National Clinical Research Center for Respiratory Diseases, Department of Respiratory and Critical Care Medicine, Beijing Hospital, Beijing 100730, China. Email: suntieying3@hotmail.com.
authors.forename: Tieying
authors.initials: T
authors.lastname: Sun
authors.affiliation: National Clinical Research Center for Respiratory Diseases, Department of Respiratory and Critical Care Medicine, Beijing Hospital, Beijing 100730, China.
authors.forename: Chen
authors.initials: C
authors.lastname: Wang
mesh_terms: D000368:Aged; D005260:Female; D006761:Hospitals; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications*; D008297:Male; D011379:Prognosis; D011655:Pulmonary Embolism; D012307:Risk Factors; D054556:Venous Thromboembolism / Q000628:therapy*